Company Overview of Intarcia Therapeutics, Inc.
Intarcia Therapeutics, Inc., a biopharmaceutical company, develops therapies to enhance treatment outcomes by optimizing and improving the administration and tolerability of drug therapies. The company develops ITCA 650, a Phase 3 clinical program for type 2 diabetes that consists of 4 separate clinical trials. Its products includes a cylindrical titanium alloy reservoir that is inserted under the skin that allows the water from the extracellular fluid to enter the device at one end by diffusing through a semi-permeable membrane directly into a salt osmotic engine that expands to drive a piston at a controlled rate, and forces the drug formulation to be released in a consistent way through t...
155 Seaport Boulevard
Boston, MA 02210
Founded in 1995
Key Executives for Intarcia Therapeutics, Inc.
Executive Chairman, Chief Executive Officer and President
Chief Financial Officer and Vice President of Finance & Operations
Chief Scientific Officer and Vice President
Chief Legal Officer, Vice President and General Counsel
Compensation as of Fiscal Year 2015.
Intarcia Therapeutics, Inc. Key Developments
Intarcia Therapeutics, Inc. Appoints Anthony Hurley as VP, Global Commercial Manufacturing and Operations
Apr 5 16
Intarcia Therapeutics, Inc. announced that Anthony Hurley has joined the company in the role of VP, Global Commercial Manufacturing and Operations, based in Hayward, CA. Tony is an executive officer of the company and serves as a member of the Leadership Team, reporting directly to Chairman, President and CEO, Kurt Graves. Most recently Tony served as Genentech's VP, Head of Global External Manufacturing – Biologics. He spent the last eleven years of his career at Genentech in positions of increasing responsibility including Head of South San Francisco Manufacturing Operations and Head of Global Quality Biologics for both Drug Substance and Drug Product. His immediate responsibilities at Intarcia will be to provide the manufacturing support for the potential global launch of Intarcia's novel drug-device platform to treat type 2 diabetes. Specifically, Mr. Hurley will lead and continue to build out the commercial manufacturing team necessary to accomplish the commercial production/scale-up and facility expansions in the U.S. and abroad. The new position is part of Intarcia's rapid expansion to bring new capabilities in-house to further advance the company's disruptive innovations to market so that one of the world's most prevalent, costly and devastating chronic diseases - type 2 diabetes – might be more effectively addressed. He will serve as an executive leader in the company broadly, shouldering a large and mission-critical responsibility for the scale-up of ITCA 650 for planned global launch. Tony and the rest of the team in Hayward will also finalize plans and important work on second manufacturing facility in Ireland, and eventually progressing novel pipeline programs when they reach the right stage of development. Prior to his decade-long career in senior positions at Genentech, Inc., Mr. Hurley spent seventeen years in positions of increasing responsibility at GlaxoSmithKline (GSK) from 1987 to 2004, beginning as a Primary Plant Process Engineer and advancing through the ranks to his most senior role as Site Director, Upper Merion Anti-Infectives Operations, where he oversaw 280 employees. Before this, Tony spent two years as at Schering Plough as a Pilot Plant Engineer/Supervisor.
Intarcia Therapeutics, Inc. Appoints John Yee as Vice President, Head of Global Medical Affairs, Safety and Operations
Feb 8 16
Intarcia Therapeutics, Inc. announced the appointment of John Yee, MD, MPH, into the newly created role of Vice President, Head of Global Medical Affairs, Safety and Operations. Dr. Yee has two decades of leadership experience at leading pharmaceutical, biotechnology, and health care companies, and at a major academic medical center. Most recently Dr. Yee served as VP, Head of Medical Affairs, US Diabetes, and VP, US Head Medical Officer at AstraZeneca, where he led medical affairs across all therapeutic areas, and led the medical launch of multiple cardiovascular and metabolic products, including: Bydureon® (exenatide extended-release) for injectable suspension, Farxiga® (dapagliflozin), Xigduo™ XR (dapagliflozin and metformin HCI extended release tablets), Myalept® (metreleptin) for injection, and Brilinta® (ticagrelor tablets). In his new role at the company, Dr. Yee will be a member of the Leadership Team and an Executive Officer of the company, and he will report directly to Kurt Graves, Chairman, President and CEO.
Intarcia Therapeutics, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:30 AM
Jan 19 16
Intarcia Therapeutics, Inc. Presents at The LEERINK Partners 5th Annual Global Healthcare Conference, Feb-10-2016 11:30 AM. Venue: The Waldorf Astoria, New York, New York, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions